FDA Warning on Xylazine: Mitigating Human Risk | by: Sumeet Singh, Founder & Chairman | Article Posted: November 6, 2023 | The U.S. Food and Drug Administration (FDA) has issued a warning regarding mitigating risks from human Xylazine exposure. FDA has not...
New York Opioid Tax & Minnesota Regulatory Fee Changes As the changes to state laws per DSCSA continues to sweep the country, the Opioid...
NY Pharmacies Unite to Take Aim at PBMs Originally published on Nov 29, 2018. Earlier this month over 500 independent pharmacy owners came together...
Big Changes on Horizon for Regulation of Controlled Substances Continued political and public pressure has pushed sweeping changes to how the...
DEA Insights from the 2018 DEA Diversion Conference The DEA hosted a conference in San Antonio, TX that addressed multiple aspects of how those that...
PBM Pressure: Politics, Prospects and Pass-Throughs Cigna & Express Scripts Follow Aetna & Caremark Lead for Fighting Chance It is no secret...
Telehealth Growth Trajectory Continues Upward Telehealth technology presents a unique opportunity to revolutionize multiple aspects of healthcare....
